Sight Sciences (SGHT) Common Equity (2020 - 2026)

Sight Sciences' Common Equity history runs 7 years deep, the most recent figure standing at $53.9 million for Q1 2026.

• On a quarterly basis, Common Equity fell 30.56% year-over-year to $53.9 million in Q1 2026; TTM through Mar 2026 was $53.9 million, a 30.56% decrease from a year earlier, with the FY2025 full-year figure at $63.9 million, down 26.94% from the prior year.
• Common Equity retreated to $53.9 million in Q1 2026 per SGHT's latest filing, from $63.9 million in the prior quarter.
• Across five years, Common Equity topped out at $211.9 million in Q1 2022 and bottomed at $53.9 million in Q1 2026.
• The 5-year median for Common Equity is $109.2 million (2024), against an average of $117.0 million.
• Across the five-year window, Common Equity surged 310.23% in 2022 and tumbled 32.3% in 2025, its largest moves.
• Year by year, Common Equity stood at $160.1 million in 2022, then declined by 24.9% to $120.2 million in 2023, then declined by 27.19% to $87.5 million in 2024, then retreated by 26.94% to $63.9 million in 2025, then fell by 15.7% to $53.9 million in 2026.
• Per Business Quant, the three latest SGHT Common Equity figures stand at $53.9 million (Q1 2026), $63.9 million (Q4 2025), and $64.3 million (Q3 2025).